To include your compound in the COVID-19 Resource Center, submit it here.

Autolymphocyte therapy data

CLTX (Newton, Mass.) presented Phase III results from extended treatment of 150 patients who had completed an initial six-month therapy. The data,

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE